Free tool
FAERS Monitor: Rozlytrek
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212725 or its brand name (Rozlytrek, Entrectinib). Reports on generic versions are filed under their own applications.
Reports
1,691
Serious
1,103
65% of reports
Hospitalization
356
Death reported
275
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use173
- dizziness157
- death135
- disease progression119
- taste disorder74
- no adverse event72
- drug ineffective69
- constipation68
- blood creatinine increased66
- fatigue64
- diarrhoea63
- renal impairment62
- nausea59
- weight increased54
- cardiac failure50
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 32 |
| 2020 | 125 |
| 2021 | 233 |
| 2022 | 288 |
| 2023 | 263 |
| 2024 | 467 |
| 2025 | 172 |
| 2026 | 109 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,468 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| taste disorderSignal | 74 | 45.5 | 36.4 | 3,170 |
| blood creatinine increasedSignal | 66 | 12.6 | 9.9 | 694 |
| disease progressionSignal | 119 | 12.5 | 10.5 | 1,256 |
| renal impairmentSignal | 62 | 9.2 | 7.2 | 446 |
| cardiac failureSignal | 50 | 7.8 | 5.9 | 288 |
| no adverse eventSignal | 72 | 4.9 | 3.9 | 224 |
| dizzinessSignal | 157 | 3.9 | 3.4 | 346 |
| constipationSignal | 68 | 3.9 | 3.1 | 144 |
| weight increasedSignal | 54 | 3.0 | 2.3 | 71 |
| off label useSignal | 173 | 2.5 | 2.1 | 155 |
| death | 135 | 1.9 | 1.7 | 64 |
| diarrhoea | 63 | 1.2 | 1.0 | 2 |
| fatigue | 64 | 1.0 | 0.8 | 0 |
| nausea | 59 | 0.9 | 0.7 | 0 |
| drug ineffective | 69 | 0.7 | 0.5 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.